Lineage Cell Therapeutics, Inc.
LCTX
Rank in Stocks
#15259
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company,... Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Share Price
$1.08
Last synced: 2026-11-09
Market Cap
$273.14M
Change (1 day)
5.88%
Change (1 year)
-40.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lineage Cell Therapeutics, Inc. (LCTX)
Category
Healthcare
EPS for Lineage Cell Therapeutics, Inc. (LCTX)
EPS as of June 2026 TTM: $-0.14
According to Lineage Cell Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.14. At the end of 2025 the company had an EPS of $-0.28, a decrease compared to its 2024 EPS of $-0.09.
EPS history for Lineage Cell Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.14 | -50.00% |
| 2025 | $-0.28 | 201.08% |
| 2024 | $-0.09 | -22.50% |
| 2023 | $-0.12 | -20.00% |
| 2022 | $-0.15 | -42.31% |
| 2021 | $-0.26 | 85.71% |
| 2020 | $-0.14 | 72.20% |
| 2019 | $-0.08 | -77.42% |
| 2018 | $-0.36 | 111.76% |
| 2017 | $-0.17 | -148.57% |
| 2016 | $0.35 | -159.32% |
| 2015 | $-0.59 | 7.27% |
| 2014 | $-0.55 | -32.10% |
| 2013 | $-0.81 | 84.09% |
| 2012 | $-0.44 | 25.71% |
| 2011 | $-0.35 | 25.00% |
| 2010 | $-0.28 | 55.56% |
| 2009 | $-0.18 | 12.50% |
| 2008 | $-0.16 | 154.37% |
| 2007 | $-0.06 | -23.94% |
| 2006 | $-0.08 | -31.08% |
| 2005 | $-0.12 | -33.33% |
| 2004 | $-0.18 | 50.00% |
| 2003 | $-0.12 | -47.83% |
| 2002 | $-0.23 | -28.13% |
| 2001 | $-0.32 | -28.89% |
| 2000 | $-0.45 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -11,285.71% |
US
|
|
| $-7.07 | 4,950.00% |
US
|
|
| $-5.29 | 3,678.57% |
AU
|
|
| $12.88 | -9,300.07% |
BE
|
|
| $21.56 | -15,500.00% |
NL
|
Questions about Lineage Cell Therapeutics, Inc.'s earnings per share (EPS)
What is Lineage Cell Therapeutics, Inc.'s earnings per share (EPS)?
Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.14, as of Jun 2026.
What was Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) was $-0.28, compared with $-0.09 in 2024.
How has Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-0.09) and lowest in 2025 ($-0.28).
How does Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Lineage Cell Therapeutics, Inc.'s earnings per share (EPS) ($-0.14) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.